Factrel
(Gonadorelin)ApprovedSmall molecule
FerringFactrel is one of 38 small molecule programs targeting Polycystic Ovary Syndrome. It is currently in Approved.
1
Indications
4
Total Trials
2
Active Trials
37
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
175 competitors in Polycystic Ovary Syndrome
#DrugCompanyPhaseTrials
1Glucophage
Boehringer IngelheimPhase 3
Factrel
FerringApproved
Sequential Lenvatinib
SSun Yat-sen University
Phase 3
Clomid
FerringPreclinical
Oral Contraceptive Pill
WWayne State University
Phase 3
Precose
BayerPreclinical
Proglycem
TevaPreclinical
Clomid
EMD SeronoPreclinical
Cetrotide
EMD SeronoPreclinical
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Polycystic Ovary Syndrome1 trial
Postmenopausal Women1 trial
Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women
Active, not recruiting·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 1·NCT04037605·5 enrolled
Regulatory
FDA Approval Timeline[4]
Sep 30, 1982
FACTREL
NDA NDA018123
Oct 10, 1989
LUTREPULSE KIT
NDA NDA019687
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gonadorelin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]